These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27256522)

  • 1. Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
    Sathyapalan T; Dakroury Y; Ahmed L; Elshewehy AM; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2016 Oct; 85(4):671-3. PubMed ID: 27256522
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome.
    Sathyapalan T; Cho L; Kilpatrick ES; Le Roux CW; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):423-5. PubMed ID: 19489873
    [No Abstract]   [Full Text] [Related]  

  • 3. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
    Dawson AJ; Kilpatrick ES; Coady AM; Elshewehy AMM; Dakroury Y; Ahmed L; Atkin SL; Sathyapalan T
    BMC Endocr Disord; 2017 Jul; 17(1):41. PubMed ID: 28705172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome.
    Seibel SA; Chou KH; Capp E; Spritzer PM; von Eye Corleta H
    Eur J Obstet Gynecol Reprod Biol; 2008 May; 138(1):122-4. PubMed ID: 17350746
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment.
    Cheng F; Zhao L; Wu Y; Huang T; Yang G; Zhang Z; Wu Y; Jia F; Wu J; Chen C; Liu D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):386-93. PubMed ID: 26387747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.
    Sathyapalan T; Cho LW; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):931-5. PubMed ID: 18410553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
    Diamanti-Kandarakis E; Spina G; Kouli C; Migdalis I
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4666-73. PubMed ID: 11600523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
    Sathyapalan T; Javed Z; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2017 Mar; 86(3):384-387. PubMed ID: 27651218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).
    Sathyapalan T; Cho LW; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):124-8. PubMed ID: 19128368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F; Zamani MM; Heshmat R; Moini nia F
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome.
    Yasmin E; Glanville J; Barth J; Balen AH
    Eur J Obstet Gynecol Reprod Biol; 2011 May; 156(1):67-71. PubMed ID: 21277073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S; Rustgi VK
    Clin Liver Dis; 2016 May; 20(2):351-64. PubMed ID: 27063274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
    Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
    Kilic S; Yilmaz N; Zulfikaroglu E; Erdogan G; Aydin M; Batioglu S
    Gynecol Endocrinol; 2011 Sep; 27(9):622-9. PubMed ID: 21105835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic manifestations of women with polycystic ovary syndrome.
    Chen MJ; Ho HN
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome.
    Oppelt PG; Mueller A; Jentsch K; Kronawitter D; Reissmann C; Dittrich R; Beckmann MW; Cupisti S
    Exp Clin Endocrinol Diabetes; 2010 Oct; 118(9):633-7. PubMed ID: 19998243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.
    Jakubowska J; Bohdanowicz-Pawlak A; Milewicz A; Szymczak J; Bednarek-Tupikowska G; Demissie M
    Gynecol Endocrinol; 2008 Jul; 24(7):378-84. PubMed ID: 18645710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome.
    Kapoor S
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):339. PubMed ID: 18625002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.